Evaluation of the Effects of Empagliflozin on Acute Lung Injury in Rat Intestinal Ischemia-Reperfusion Model
Abstract
Abstract Background: Empagliflozin is a selective sodium-glucose co-transporter (SGLT2) inhibitor that is accepted for the treatment of type 2 diabetes. Positive effects of empagliflozin on systems other than diabetes have been detected. The aim of this study is to evaluate the role of empagliflozin on acute lung injury induced by intestinal ischemia/ reperfusion (I/R). Materials and methods: A total of 27 male Wistar albino rats were divided into 3 groups: sham, I/R, and I/R+ empagliflozin; each group contains 9 animals. Sham group animals underwent laparotomy without I/R injury. After I/R groups animals underwent laparotomy, 1 h of superior mesenteric artery ligation was followed by 2 h of reperfusion. In the empagliflozin group, 7 days before I/R, empagliflozin (30 mg/kg) was administered by gastric gavage. All animals were killed at the end of reperfusion and lung tissue samples were obtained for immunohistochemical staining and histopathological investigation in all groups. Results: Serum glucose, AST, ALT, creatinine, native thiol, total thiol, and disulfide levels and disulfide–native thiol, disulfide–total thiol, and native thiol–total thiol ratios as well as the IMA levels were analyzed and compared among the groups. While intestinal I/R significantly increases serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine levels; Thiol/Disulfide did not cause any change in homeostasis parameters and IMA level. Empagliflozin treatment had no…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.